瑞波西汀与氟西汀治疗抑郁症对照研究

目的 评价瑞波西汀与氟西汀治疗抑郁症的临床疗效和安全性。方法将69例抑郁症患者随机分为两组，研究组35例，口服瑞波西汀治疗，对照组34例，口服氟西汀治疗，观察6周。于治疗前及治疗1周、2周、4周、6周末采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果研究组治疗1周末起、对照组治疗2周末起汉密顿抑郁量表总分均较治疗前有显著性下降（P〈0．01），研究组治疗1周末较对照组下降更显著（P〈0．05），有效率为62．9％，显著高于对照组（23．5％，P〈0．01）；治疗6周末治愈率为62．9％、有效率91．4％，与对照组（61．8％、91．2％）均无显著性差异（P〉0．05）。治疗后两组副反应量表评分随着治疗时间的延续均呈持续性下降，治疗2周末起，研究组副反应量表评分均显著低于对照组（P〈0．05或0．01）。结论瑞波西汀治疗抑郁症疗效显著，且与氟西汀相当，但瑞波西汀起效更快，不良反应轻微，安全性更高，耐受性良好，长期应用不影响认知功能。

A controlled study of reboxetine versus fluoxetine in depression

Objective To evaluate the clinical efficacy and adverse reactions of reboxetine and fluoxetine in the treatment of depression. Methods Sixty-nine depression patients were randomly divided into research group（n=35） taking orally reboxetine and control group（n=34） doing fluoxetine for 6 weeks. Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 1st, 2nd, 4th and 6th week. Results Compared with pretreatment, total scores of the HAMD lowered more significantly since the end of the 1st week in the research and the 2nd in the control group（P〈0.01）, so did at the end of the 1 st week in the research than in the control group（P〈0.05）, the effective rate were significantly higher in the research（62.9%） than in the control group（23.5G ,P〈0.01）; at the end of the 6th week, there were no significant differences in recovery and effective rate （research group 62.9% and 91.4%; control group 61.8% and 91.2%, P〉0.05）. After treatment, the TESS scores of both groups lowered continously with treatment, since the end of the 2nd week the TESS score s of the research were all significantly lower than those of the control group（P〈0.05 or 0.01）. Conclusion Reboxetine has an evident effect equivalent to fluoxetine in depression, but takes effect more rapidly, has mild adverse reactions, higher safety, is welltoleranted, and long-term application does not influence cognitive function.